Drug treatment for hypertensive patients in special situations: Diabetes and hypertension

Clinical and Experimental Hypertension

Volumn 21, Issue 5-6, 1999, Pages 895-906

  Mogensen, Carl Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antihypertensive treatment; Cardiovascular disease; Hypertension; Microalbuminuria; Renal disease; Risk factors; Type 1 and 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CONFERENCE PAPER; DIABETIC NEPHROPATHY; DRUG MECHANISM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; METABOLIC DISORDER; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

EID: 0032794082     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909061018     Document Type: Conference Paper

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med, 1993; 329;977-86.
2. UKPDS 33. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with Type 2 diabetes. Lancet 1998; 352: 837-853.
3. UKPDS 34. Effect of an intensive blood glucose control policy with metformin on complications in Type 2 diabetic patients. Lancet 1998; 352:854-865.
4. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med, 1998; 158: 134-140.
5. Wang PH, Lau J, Chalmers CT. Meta-analysis of effects of intensive blood-glocuse control on late complications of type 1 diabetes. Lancet, 1993; 341:1306-1309.
6. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment (review). Diabetologia, 1998; 41:745-759.
7. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S, et al for United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 38. BMJ 1998; 317:703-713.
8. Cooper M, McNally P. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria, 419-434. The kidney and hypertension in diabetes mellitus, Mogensen CE,. 4th ed., Kluwer Academic Publ, 1998.
9. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive patients with type 2 diabetes mellitus. A randomized controlled trial. Ann. Intern. Med, 1998; 128: 982-988.
10. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians, N Engl J Med, 1980; 302(12):645-650. 419-434
11. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276(23): 1886-92.
12. Holman R, Turner R, Stratton I, Cull C, Frighi V, Manley S, et al for United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 39. BMJ 1998; 317:713-720.
13. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco RG, Strollo G, Strollo F. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trials (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
14. Tuomilehto J, Rastenyte D, Thisj L, Staessen J. Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertension in Europe treated with nitrendipine-based antihypertensive therapy (Syst-Eur-Trial). Diabetes 1998; 47:A54 (abstract).
15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet, 1998; 351: 1755-62.
16. Estacio RO, Jeffers BW, Hiatt RA, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
17. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ, 1998; 316: 823-8.
18. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ, 1982; 285:685-688.
19. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993; 329:1456-1462.
20. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet, 1997; 349: 1787-92.
21. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes, 1997; 46, suppl. 2: S104-11.
22. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-289.
23. Nielsen FS, Rossing P, Gall M-A, Skott P, Smidt UM and Parving H-H. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects. With diabetic nephropathy. Diabetes, 1997; 46:1182-8.
24. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Principal results of the Captopril Prevention Project (CAPPP). Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet in press.
25. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Nosadini R and The Italian Microalbuminuria Study Group in IDDM. Effects of Lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care, 1998: 21(1): 104-111.
26. Mogensen CE (ed.). The kidney and hypertension in diabetes mellitus. Kluwer Academic Publishers, Boston, Dordrecth, London, 1998.